Joint Formulary & PAD

Nifedipine - Raynaud's Phenomenon

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Capsules
Associated Icons :
SPC
Restrictions / Comments :
Preferred
 

Status 2

Green (see narrative)
Formulations :
  • Modified release capsules
  • Modified release tablets
Associated Icons :
Off Label
SPC
Restrictions / Comments :
Important

Twice-daily preparations only. Off-label.

For use when immediate release nifedipine is not tolerated.

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Nifedipine
Indication :
Raynaud's Phenomenon
Group Name :
Keywords :
Raynaud's disease, Raynaud's syndrome
Brand Names Include :
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0
Traffic Light Entries :
2

Committee Recommendations (1)

The Surrey Heartlands Area Prescribing Committee agreed the traffic light status of this drug and indication as part of the Joint Formulary review.

Other Indications

Below are listed other indications that Nifedipine is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Raynaud's Phenomenon.